Holen Sie sich die Stockscreener-App
9.18
3.85%
0.34
Handel nachbörslich:
9.23
0.05
+0.54%
Cartesian Therapeutics Inc Aktie (RNAC) Neueste Nachrichten
Cartesian Therapeutics Inc. (NASDAQ: RNAC) Share Price, RNAC Stock News, RNAC Share Price & Updates - kalkine.ca
Barclays PLC (RNAC) discloses 1.76M-share, 5.99% holding in Cartesian Therapeutics - Stock Titan
Mizuho Securities Maintains Cartesian Therapeutics(RNAC.US) With Buy Rating, Maintains Target Price $40 - Moomoo
HC Wainwright Analysts Lower Earnings Estimates for RNAC - MarketBeat
Cartesian Therapeutics Inc (RNAC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cartesian Therapeutics Advances RNA Cell Therapy Pipeline; Wedbush Sets $38 Price Target - RTTNews
Cartesian Therapeutics (NASDAQ:RNAC) Announces Quarterly Earnings Results - MarketBeat
Cartesian Therapeutics (NASDAQ:RNAC) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
A Quick Look at Today's Ratings for Cartesian Therapeutics(RNAC.US), With a Forecast Between $25 to $44 - Moomoo
Cartesian Therapeutics Inc (RNAC) Stock News Today - TradingKey
Cartesian Therapeutics Announces New Employment Inducement Grants - GlobeNewswire
Four new employees get options for 115,250 Cartesian shares - Stock Titan
Cartesian Therapeutics earnings beat by $1.34, revenue fell short of estimates - Investing.com Canada
Cartesian Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Cartesian Therapeutics Q2 2026 earnings: R&D spending rises as Phase 3 advances - TradingKey
Cartesian Therapeutics Reports Q2 2026 Results, Advances Descartes-08 Clinical Trials and WestGene In Vivo Partnership - Quiver Quantitative
Cartesian Therapeutics reports Q2 2026: $149.3M cash; net income $15.8M; Phase 3 MG data expected 1Q27 - TradingView
Cartesian Therapeutics (Nasdaq: RNAC) Q2 earnings boosted by CVR revaluation - Stock Titan
Cartesian Therapeutics 2Q Research and Development Expenses $20.4M >RNAC - Moomoo
RNAC Q2'26 Earnings: EPS estimate is (0.88) USD - TradingView
Cartesian Therapeutics Inc expected to post a loss of 87 cents a shareEarnings Preview - TradingView
Price to sales forward of Cartesian Therapeutics, Inc. – NASDAQ:RNAC - TradingView
Cartesian Therapeutics (NASDAQ:RNAC) Raised to Hold at Zacks Research - MarketBeat
Cartesian Therapeutics (RNAC) Expected to Announce Earnings on Thursday - MarketBeat
Cartesian Therapeutics, Inc. Revenue Breakdown – NASDAQ:RNAC - TradingView
Cartesian Therapeutics (NASDAQ:RNAC) Shares Down 1.1%Here's What Happened - MarketBeat
Cartesian Therapeutics Inc (RNAC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cartesian Therapeutics Inc (RNAC) Cash Flow - TradingKey
Cartesian Therapeutics, Inc. Revenue Breakdown – FWB:1S70 - TradingView
Cartesian Therapeutics Inc (RNAC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cartesian Therapeutics Inc (RNAC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
RNAC|Cartesian Therapeutics Inc|Price:8.690|Chg%:-0.160 - TradingKey
Cartesian Therapeutics Inc (RNAC) Balance Sheet - TradingKey
Cartesian Therapeutics Inc (RNAC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
RNAC|Cartesian Therapeutics Inc|Price:7.780|Chg%:-0.100 - TradingKey
TradingKey - TradingKey
Cartesian Therapeutics, Inc. Revenue Breakdown – LS:A407YS - TradingView
ETFs Investing in Cartesian Therapeutics, Inc. Stocks - TradingView
JPMorgan Chase & Co. (RNAC) discloses 4.8% beneficial stake in Cartesian Therapeutics - Stock Titan
Enterprise value to EBITDA forward of Cartesian Therapeutics, Inc. – NASDAQ:RNAC - TradingView
Cartesian Therapeutics Inc (RNAC) - MSN
Cartesian Therapeutics Inc. : RNAC - 24/7 Wall St.
Cartesian Therapeutics Inc. (RNAC) Q1 2026 Earnings: Wider-Than-Expected Loss Highlights Pre-Revenue Pipeline ProgressTax Rate Impact - dars.gov.et
Emerging Therapies Transforming the Myasthenia Gravis Market by DelveInsight | Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Roche, Janssen R&D, Immunovant Sciences GmbH, Argenx-Halozyme - Barchart.com
Wedbush Initiates Coverage of Cartesian Therapeutics (RNAC) with Outperform Recommendation - MSN
Cartesian offers 8 new hires stock options worth 238,700 shares - Stock Titan
BTIG Maintains Cartesian Therapeutics(RNAC.US) With Buy Rating, Maintains Target Price $44 - Moomoo
RNACCartesian Therapeutics Inc Latest SEC Filings - Finviz
Cartesian Therapeutics (RNAC) Q1 2026 Earnings: Wider-than-Expected Loss as Clinical-Stage Pipeline Advances - dars.gov.et
Cartesian Therapeutics (RNAC) Q1 2026 Earnings: Wider-Than-Expected Loss, but Shares Rise 5.49%Guidance Update - dars.gov.et
Price to earnings forward of Cartesian Therapeutics, Inc. – NASDAQ:RNAC - TradingView
Cabaletta Bio: The Market Sold The EULAR News, I'm Buying (NASDAQ:CABA) - Seeking Alpha
RNAC Forecast — Price Target — Prediction for 2027 - TradingView
Cartesian Therapeutics, Inc. Actuals & Estimates (NASDAQ:RNAC) - TradingView
Enterprise value to EBIT forward of Cartesian Therapeutics, Inc. – NASDAQ:RNAC - TradingView
Price to sales forward of Cartesian Therapeutics, Inc. – GETTEX:1S70 - TradingView
Price to book forward of Cartesian Therapeutics, Inc. – GETTEX:1S70 - TradingView
Cartesian Therapeutics Inc (RNAC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cartesian Therapeutics Shareholders Back Directors and Governance Measures - The Globe and Mail
Cartesian Therapeutics Inc (RNAC) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cartesian Therapeutics Inc (RNAC) Institutional Confidence - TradingKey
Shareholders of Cartesian Therapeutics (NASDAQ: RNAC) back board, pay and auditor - Stock Titan
Cartesian Therapeutics Inc (RNAC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
1.80%
1.77%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):